

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5874547

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NIMALI PIYUSHIKA WITHANA	03/05/2019
ARUNA MANI	03/05/2019
STINA MUI SINGEL	03/05/2019
RECEIVING PARTY DATA	
Name:	GENENTECH, INC.
Street Address:	1 DNA WAY
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080-4990
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62782116
Application Number:	62822556
Application Number:	16716815
PCT Number:	US2019066684
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-467-8720
Email:	kokkac@gene.com
Correspondent Name:	CHIAKI KOKKA
Address Line 1:	1 DNA WAY
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P35160-US/US-1/US-2 & WO
NAME OF SUBMITTER:	CHIAKI KOKKA
SIGNATURE:	/Chiaki Kokka/
DATE SIGNED:	12/18/2019
Total Attachments: 15	

source=P35160 Executed Assignment I-As#page1.tif
source=P35160 Executed Assignment I-As#page2.tif
source=P35160 Executed Assignment I-As#page3.tif
source=P35160 Executed Assignment I-As#page4.tif
source=P35160 Executed Assignment I-As#page5.tif
source=P35160 Executed Assignment I-As#page6.tif
source=P35160 Executed Assignment I-As#page7.tif
source=P35160 Executed Assignment I-As#page8.tif
source=P35160 Executed Assignment I-As#page9.tif
source=P35160 Executed Assignment I-As#page10.tif
source=P35160 Executed Assignment I-As#page11.tif
source=P35160 Executed Assignment I-As#page12.tif
source=P35160 Executed Assignment I-As#page13.tif
source=P35160 Executed Assignment I-As#page14.tif
source=P35160 Executed Assignment I-As#page15.tif

CONFIRMATORY ASSIGNMENT

WHEREAS, **Nimali Piyushika WITHANA** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.


ASSIGNMENT I-A

Family No.: P35160

Genentech File Identifier: Treatment of breast cancer with combination therapy comprising an AKT inhibitor, a taxane, and a PD-L1 antibody

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of March 5, 2019, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof.




Nimali Piyushika WITHANA

Mailing address:

1 DNA Way
South San Francisco, CA 94080

Citizenship: **NZ**



GENENTECH, INC. *Hand*

Name: Todd M. Crissey

Assistant General Counsel

Title: Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35160-US	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L 1 INHIBITOR	62/782,116	December 19, 2018

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P35160

Genentech File Identifier: Treatment of breast cancer with combination therapy comprising an AKT inhibitor, a taxane, and a PD-L1 antibody

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35160-US	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L 1 INHIBITOR	62/782,116	December 19, 2018
P35160-US-1	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	62/822,556	March 22, 2019
P35160-GC	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	GC 2019-38848	December 17, 2019
P35160-TW	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	108146152	December 17, 2019
P35160-US-2	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	16/716,815	December 17, 2019
P35160-WO	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	PCT/US2019/066684	December 17, 2019

CONFIRMATORY ASSIGNMENT

WHEREAS, **Aruna MANI** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P35160

Genentech File Identifier: Treatment of breast cancer with combination therapy comprising an AKT inhibitor, a taxane, and a PD-L1 antibody

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of March 5, 2019, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Aruna MANI

Mailing address:

1 DNA Way
South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Name: Todd M. Crissey
Assistant General Counsel

Title: Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35160-US	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L 1 INHIBITOR	62/782,116	December 19, 2018

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P35160

Genentech File Identifier: Treatment of breast cancer with combination therapy comprising an AKT inhibitor, a taxane, and a PD-L1 antibody

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35160-US	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L 1 INHIBITOR	62/782,116	December 19, 2018
P35160-US-1	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	62/822,556	March 22, 2019
P35160-GC	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	GC 2019-38848	December 17, 2019
P35160-TW	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	108146152	December 17, 2019
P35160-US-2	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	16/716,815	December 17, 2019
P35160-WO	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	PCT/US2019/066684	December 17, 2019

CONFIRMATORY ASSIGNMENT

WHEREAS, **Stina Mui SINGEL** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the **INVENTION** and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the **INVENTION** to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the **INVENTION**, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the **INVENTION** to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the **INVENTION** when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.


ASSIGNMENT I-A

Family No.: P35160

Genentech File Identifier: Treatment of breast cancer with combination therapy comprising an AKT inhibitor, a taxane, and a PD-L1 antibody

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of March 5, 2019, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof.



Stina Mui SINGEL

Mailing address:

1 DNA Way
South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Name: Todd M. Crissey

Assistant General Counsel

Title: Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35160-US	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L 1 INHIBITOR	62/782,116	December 19, 2018

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P35160

Genentech File Identifier: Treatment of breast cancer with combination therapy comprising an AKT inhibitor, a taxane, and a PD-L1 antibody

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35160-US	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L 1 INHIBITOR	62/782,116	December 19, 2018
P35160-US-1	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	62/822,556	March 22, 2019
P35160-GC	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	GC 2019-38848	December 17, 2019
P35160-TW	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	108146152	December 17, 2019
P35160-US-2	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	16/716,815	December 17, 2019
P35160-WO	TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR	PCT/US2019/066684	December 17, 2019